Health Care Climbs After Lilly Earnings - Health Care Roundup
Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Lilly’s profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales
Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.
Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...